Company Analysis: Affimed N.V. (AFMD)

Introduction

Affimed N.V. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company specializes in harnessing the innate immune system to target solid and hematologic tumors. Affimed's proprietary technology, known as Innate Cell Engagers (ICE®), is designed to activate natural killer (NK) cells and other immune cells to directly attack tumor cells.

Corporate Structure

• Founded: 2000
• Incorporation: Netherlands
• Headquarters: Mannheim, Germany
• Employee Count: Approximately 51-200 employees
• Key Products:
  • AFM13: Targeting CD30-positive lymphomas
  • AFM24: Targeting EGFR-expressing solid tumors
  • AFM28: Targeting CD123-expressing acute myeloid leukemia (AML)

Recent Developments and News

• Insolvency Filing: On May 13, 2025, Affimed N.V. and its subsidiary, Affimed GmbH, filed for insolvency under German law.
• Nasdaq Delisting Notification: Following the insolvency filing, Affimed received notice from Nasdaq that trading of its shares would be suspended, with a formal delisting process initiated.
• Clinical Trials: Affimed continues to conduct clinical trials for its ICE® molecules, with preliminary results reported for AFM13 and AFM24 in various studies.

Financial and Strategic Aspects

• Stock Price: As of May 16, 2025, the stock price was $0.2790, reflecting a price change of +227.85% from previous trading sessions.
• Market Capitalization: Approximately $4.57 million.
• Revenue (TTM): $5.64 million, with a net income loss of $69.97 million.
• Cash Position: As of December 31, 2024, Affimed reported approximately €13.0 million in cash, which is projected to fund operations until the end of Q2 2025.
• Debt: The company has a total debt-to-equity ratio of 74.96%.

Market Position and Industry Context

Affimed operates within the biotechnology sector, specifically in immuno-oncology. The company’s focus on innate immunity therapies positions it among other biotech firms aiming to advance cancer treatments. The recent insolvency filing and Nasdaq delisting notification may affect its operational strategies and future financing prospects.

TL;DR

Affimed N.V. filed for insolvency on May 13, 2025, leading to a suspension of its shares on Nasdaq. The company reported a stock price of $0.2790 as of May 16, 2025, with a market cap of approximately $4.57 million. Its cash reserves are expected to last until the end of Q2 2025. The company continues to conduct clinical trials for its ICE® molecules, but its financial situation may impact future operations and market viability.